News
A new international study reveals that GLP-1 receptor agonists—commonly used for weight loss—may significantly reduce the risk of dementia in people with type 2 diabetes, outperforming metformin.
Compared with other antidiabetic drugs, semaglutide is associated with a lower risk for Alzheimer disease-related dementia in patients with type 2 diabetes.
Common medicines, including diabetes, cancer, and antiviral drugs, may offer new hope in slowing dementia. UK researchers, including a team from the University of Cambridge, have uncovered strong ...
GLP-1s - which mimic the effects of the hormone that stimulates insulin release, suppressing glucagon, and slowing gastric emptying - also have a range of other benefits.
FAT jabs are better than widely prescribed metformin when it comes to curbing dementia risk in people with type 2 diabetes, ...
For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke, and all-cause mortality compared with other ...
A new study suggests that drugs like Ozempic and Mounjaro may reduce dementia risk. Researchers at the University of Galway found a 45% lower risk in ...
Weight-loss injections, including popular drugs like Wegovy and Mounjaro, may offer a protective shield against serious ...
Researchers found that the active ingredient in Ozempic may lower the risk of dementia in people with type 2 diabetes.
Newly published research claims those taking GLP-1 jabs are at a 37 percent lower risk of dementia than those on the ...
A new scientific study has found that weight loss jabs such as Mounjaro and Ozempic can help protect against serious health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results